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doi:10.1016/j.jds.2011.03.007Abstract Background/purpose: The aim of this study was to examine a new procedure of
simple freezing without the need of thrombin activation to retain and store growth factors
(GFs) from platelet concentrates for up to 6 months.
Materials and methods: After being re-suspended with Tyrode’s solution, platelet suspensions
were divided into four groups. In the negative control group, platelet supernatants were
collected after centrifugation and then frozen at 70C until being tested. In the frozen group,
platelet suspensions were directly frozen and stored at 70C; centrifugation was postponed
until just before testing. In the thrombin and post-thrombin groups, the procedures were the
same as those of the previous two groups, respectively, except that thrombin was added
before centrifugation. Concentrations of platelet-derived GF-AB and tumor GF-b1 were as-
sayed by an ELISA at 0 (the day on which the experiment began), 1, 2, and 4 months in first
three groups (Experiment 1), and in all four groups at 6 months (Experiment 2).
Results: Similar platelet-derived GF-AB and transforming GF-b1 concentrations were recorded
in the frozen and thrombin groups with up to 4 months of storage. After 6 months of storage,
similar concentrations were recorded among the frozen, thrombin, and post-thrombin groups.t of Periodontology, School of Dentistry, National Defense Medical Center, 114 No.161, Section 6,
City 114, Taiwan, ROC. Tel.: þ886 2 87927150; fax: þ886 2 87927145.
ed.net.tw (C.-Y. Chiang).
iation for Dental Sciences of the Republic of China. Published by Elsevier Taiwan LLC. All rights reserved.
Growth factors retained after frozen storage of platelet concentrates 103Conclusions: Because of similar concentrations of GFs in all groups, except for the negative
control group, after being stored for up to 6 months, we suggest that the concentration of
GFs of platelet concentrates can be maintained for at least 6 months, and that GFs in platelet
concentrates can be obtained by means of direct freezing, without the necessity of thrombin
activation.
Copyright ª 2011, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.Introduction
The application of autologous platelet concentrates
(platelet-rich-plasma; PRP) was introduced to various
dental procedures,1e5 including periodontal regener-
ation6e8 and dental implantations,9,10 because of the
abundance of growth factors (GFs).11 The exact effects of
platelet concentrates on bone regeneration are still under
investigation. Several controlled clinical studies showed
that the use of platelet concentrates may produce favor-
able outcomes in periodontal intrabony defects12,13 and in
the pocket distal to the mandibular second molar after
extraction of the third molar.2 Animal studies demonstrated
a greater volume of bone formation around a peri-implant
when platelet concentrates were applied.14,15 However, an
opposite finding that autologous platelet concentrates did
not seem to have a notable influence on periodontal and
bone healing or radiographic outcomes following peri-
odontal regenerative procedures was also reported.16,17
A critical procedure during platelet concentrate prepa-
ration is the release of the GFs from activated platelets.
Thrombin treatment is commonly recommended nowadays
for fresh blood samples to achieve optimal results.1,3,18,19 In
this study, a convenient physical freezing technique was
tested for storing GFs from platelet concentrates by freezing
for up to 6 months without the need of thrombin stimulation.
This technique allows advance, simpler preparation of fresh
platelet concentrates to avoid extra work on the day of
surgery, and also can save un-used blood for later use.
Materials and methods
Preparation and grouping of platelet concentrates
Platelet concentrates (25 mL/bag) were obtained from
250 mL of whole blood of healthy volunteer donors at the
Taipei Blood Donation Center, Taipei, Taiwan. After centri-
fugation for 10 minutes (at 2000 rpm and 25C), platelet
suspensions were obtained by gently re-suspending them in
25 mL of Tyrode’s solution (Sigma, St. Louis, MO, USA) as in
our previous studies.20,21 Numbers of platelet in the
suspensions were measured with the Z1 Series Coulter
Counter Cell and Particle Counter (Beckman Coulter, Full-
erton, CA, USA), and then adjusted to 2  105 and
3  105 platelets/mL. Twenty specimens of platelet suspen-
sions at 1 mL per Eppendorf tube were prepared from each
platelet bag/volunteer.
There were four groups of platelet samples prepared in
the study. The negative control group,whichwas supposed to
have no platelets, was prepared by means of centrifugationat 7500 rpm for 5 minutes, and supernatants were immedi-
ately frozen at 70C for storage until defrosting for an
enzyme-linked immunosorbent assay (ELISA) analysis. In the
second group, the frozen group, the un-centrifuged platelet
suspensions were immediately frozen at 70C for storage,
whereas centrifugation was deferred until after defrosting
was complete before testing. In the third (thrombin) group,
the procedures were similar to those in the negative control
group, except that thrombin treatment (5 units/mL, Cal-
biochem, La Jolla, CA, USA) was given before centrifugation
(300 g for 15 minutes). In the fourth (post-thrombin) group,
the procedures were the same as those of the frozen group,
except that platelet suspensions were stored frozen for 6
months, and thrombin treatment was carried out after
defrosting but before centrifugation. Concentrations of GFs
in samples of each group were determined.
The present study was composed of two parts. In
experimental part one, GFs in the negative control, frozen,
and thrombin groups were measured at 0 (the day on which
the experiment began), 1, 2, and 4 months; whereas in
experimental part two, concentrations of GFs in all four
groups (negative control, frozen, thrombin, and post-
thrombin groups) were evaluated after 6 months of storage.
Determination of GFs (PDGF and TGF-b1)
Both platelet-derived GF (PDGF)-AB and transforming GF
(TGF)-b1 were assayed using techniques described in
previous studies.21,22 For PDGF-AB detection, commercially
available enzyme-linked immunosorbent assay (ELISA) kits
(R&D Systems, Minneapolis, MN, USA) and 1:10 diluted
supernatants were used according to the manufacturer’s
instructions. The enzyme reaction was measured using an
automatic micro-ELISA photometer (DYNEX Technologies,
Chantilly, VA, USA) at 450 nm with a minimal detectable
dose of 31.25 pg/mL. Following the above procedures,
a TGF-b1 ELISA kit (R&D Systems) and undiluted superna-
tants were used to measure the TGF-b1 concentration with
a minimal detectable dose of TGF-b1 of 7.0 pg/mL.
According to the manufacturer’s instructions, activities of
the ELISA kits could only be kept for 4 months for the
accuracy of GF detection. Consequently, a new kit was used
for the second part of the experiment.
Statistical analysis
In experimental part one, relationships among concentra-
tions of released GFs, PDGF-AB and TGF-b1 (dependent
variables), the method used to prepare platelet concen-
trates, i.e., by freezing or thrombin activation (between-
subject factor), and storage durations, i.e., 1, 2, and
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Figure 2 The concentrations of released PDGF-AB and TGF-
b1 in the negative control, freezing, thrombin, and post-
thrombin groups after 6 months storage in the experiment two
(nZ 4; means  SE; ): significant difference at P < 0.05 from
the negative control group).
104 C.-H. Gau et al4 months (within-subject factor), were evaluated by means
of a repeated-measures analysis of variance (ANOVA). A
one-way ANOVA was applied to examine GFs released from
the three different platelet concentrate preparation groups
at each observation interval in experimental part one and
from four different platelet concentrate preparation
groups at the end of 6 months in experimental part two.
Duncan’s test was applied for a post-hoc analysis, and
P < 0.05 was selected as the level of significance.
Results
In experimental part one, there was a significant difference
in concentrations of released GFs (PDGF-AB and TGF-b1)
among the three treatment groups (PZ 0.001 and 0.002 for
PDGF-AB and TGF-b1, respectively), but not among the
different time points. Significantly lower concentrations of
PDGF-AB and TGF-b1 were demonstrated in the negative
control group than in the frozen and thrombin groups at 0,
1, 2, and 4 months (Fig. 1).
In experimental part two, in which the post-thrombin
group was included, significantly lower concentrations of
PDGF-AB and TGF-b1 were observed in the negative control
group compared to any of the three other groups after
6 months of storage (Fig. 2); while there were no significant
differences in the concentrations of PDGF-AB or TGF-b1
among the frozen, thrombin, and post-thrombin groups.4210
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Figure 1 Comparisons of the concentrations of PDGF-AB and
TGF-b1 released in the negative control, freezing and thrombin
groups at the observation intervals of 0, 1, 2 and 4 months
(nZ 4; means  SE; ): significant difference at P < 0.05 from
the negative control group).Discussion
In the present study, a preservation method depending
solely on freezing was examined for the storage of GFs
released from platelet concentrates for up to 6 months. Our
results showed that the concentrations of GFs from plate-
lets could be preserved for up to 6 months of storage
(Fig. 2). The data further demonstrated that freezing,
a simple physical stimulation, easily activated similar
concentrations of GF release from platelets compared with
thrombin treatment (Figs. 1 and 2). To date, thrombin
activation to achieve GF release from freshly prepared
platelet concentrates is still commonly recommended.
However, the use of thrombin may be associated with the
formation of antibodies against clotting factors and result
in life-threatening coagulopathies.23 Studies also showed
that thrombin may act as a stimulator of bone resorp-
tion.24,25 Several biomaterials were tested to substitute for
thrombin.26,27 In our laboratory, chitosan (a poly-sugar from
the exoskeleton of crustaceans) was tested to replace
thrombin for PRP activation.21 In this study, GF release from
platelets was easily achieved after freezing.
Gradual activation of platelets during the storage of
platelet concentrates was reported in modern blood
banks.28,29 To preserve platelet viability and provide
optimal hemostatic effectiveness, an important drawback
of storage of platelet concentrates at low temperature is
the risk of spontaneous platelet activation, so-called cold-
induced activation, which was also observed.30e32 Cold-
induced activation might partly explain GF release after
storage of platelets at 70C in the present study. Similar
procedures of recording the release of GFs from platelets
after frozen storage, without thrombin treatment, were
reported in other studies.33e35 Nevertheless, this is the
first time that concentrations of GFs were released from
platelet concentrates after 6 months of storage without the
need of thrombin stimulation.
It was reported that platelet counts significantly
differed according to the donor blood, blood bank platelet
Growth factors retained after frozen storage of platelet concentrates 105concentrate preparation, and self-concentrated platelet
concentrates.36 The efficiency of platelet collection is the
main influencing factor, because the end product with
a higher platelet count produces higher GF levels.33,37
Contents of GFs in platelet concentrates also depend on
the system used for preparing the platelet concentrates.33
In the present study, platelets were obtained from a blood
bank. Consistent numbers (3  105) of platelets from the
same individual were used for each group and at each
observation interval to avoid large variations in levels of
GFs from individuals.36 Although it was observed that
varying levels of GFs were released individually (data not
shown), the favorable possibility of successful storage of
released GFs was obviously found.
Platelet concentrates are applied in surgical procedures
to deliver GFs in high concentrations to sites requiring
osseous regeneration.1,14,15,18 Several studies showed that
platelet concentrates promote the proliferation of bone
cells, osteoblasts, and bone marrow stromal cells;38e41 the
viability and proliferation of alveolar bone cells, however,
seems to be suppressed at high platelet concentrate
concentrations.42,43 The inconsistency of the effect of the
platelet count in platelet concentrates on bone regenera-
tion was demonstrated in rabbits.44 The healing rate of
bony defects in rabbits was higher with combination
treatments of platelet concentrates, stromal cells, and
bone allografts, whereas lower values were achieved with
platelet concentrate treatment alone.45 No significant
increase in bone formation was seen with the addition of
platelet concentrates to autogenous bone in cranial bony
defects compared to grafts with autogenous bone or
platelet concentrates alone.46 An in vitro study showed
that platelet concentrates produce a number of potent
effects on periodontal ligament cells, but the effects do not
just simply reflect a combination of its major known GFs.47
Confusing or controversial outcomes after application of
platelet concentrates may be related to the available
techniques. Several techniques are available for collecting
platelet concentrates; however, each method may lead to
a different product with different biology and potential
uses. To provide an objective approach to develop these
techniques, Dohan Ehrenfest and colleagues presented
a classification of different platelet concentrates.48 Four
categories were classified depending on their leucocyte and
fibrin contents: pure PRP, leucocyte- and platelet-rich
plasma, pure platelet-rich fibrin, and leucocyte- and
platelet-rich fibrin. In addition, platelet-rich fibrin was
recommended as a new generation of platelet concentrates
with a simplified preparation without biochemical blood
handling.49 Slow polymerization during the preparation of
platelet-rich fibrin seems to generate a fibrin network very
similar to the natural one, rather than processing artificial
clinical polymerization (such as the massive addition of
bovine thrombin).
In conclusion, concentrations of GFs released by platelet
concentrates with or without thrombin treatment were
compared after frozen storage in this study. Our results
demonstrated that lower concentrations of PDGF and TGF
were found in the negative control group compared to
those in the frozen, thrombin, and post-thrombin groups
after up to 6 months of storage, whereas similar levels of
GFs were detected in the latter three groups. We,therefore, suggest that the concentration of GFs of platelet
concentrates can be retained after storage at 70C for at
least 6 months, and GFs of platelet concentrates can be
obtained by means of direct freezing, regardless of whether
thrombin activation is used.Acknowledgments
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